Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
Recruiting · NCT06586593 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centre Hospitalier Universitaire de Besancon
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \[AJCC\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\'s refusal to be operated.
- Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Exclusion criteria
- Uveal melanoma
Where it is running
9 locations listed.
- CHU Angers - Angers, France
- CHU de Besançon - Besançon, France
- Hôpital Avicenne - Bobigny, France
- CH de Boulogne-sur-Mer - Boulogne-sur-Mer, France
- CHU Clermont-Ferrand - Clermont-Ferrand, France
- Centre de Lutte Contre le Cancer Léon Bérard - Lyon, France
- ICO René Gauducheau - Saint-Herblain, France
- Institut Universitaire de Cancérologie de Toulouse - Toulouse, France
- CH de Valence - Valence, France